Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Known or suspected HIV infection or impairment of immunological functions

Receipt of immunosuppressive therapy, including any systemic, including either nasal or inhaled, corticosteroids within 28 days of enrollment. Note: Cutaneous (topical) steroid treatment is not an exclusion.

Bone marrow/solid organ transplant recipient

Major congenital malformations (such as congenital cleft palate) or cytogenetic abnormalities

Previous receipt of a licensed or investigational RSV vaccine or receipt of placebo in any IMPAACT RSV study or previous receipt of or planned administration of any anti-RSV product (such as ribavirin or RSV Ig or RSV mAb)

Previous anaphylactic reaction

Previous vaccine-associated adverse reaction that was Grade 3 or above

Known hypersensitivity to any study product component

Heart disease. Note: Participants with cardiac abnormalities documented to be clinically insignificant and requiring no treatment may be enrolled

Lung disease, including any history of reactive airway disease or medically documented wheezing

Member of a household that contains, or will contain, an infant who is less than 6 months of age at the enrollment date through Day 28

Member of a household that contains another child who is, or is scheduled to be, enrolled in CIR 311, 312 or 313 AND there has been or will be an overlap in residency during that other child's participation in the study's Acute Phase (Days 0 to 28)

Member of a household that contains an immunocompromised individual, including but not limited to:

* a person who is HIV infected

* a person who has received chemotherapy within the 12 months prior to enrollment

* a person receiving immunosuppressant agents

* a person living with a solid organ or bone marrow transplant

Attends a daycare facility and shares a room with infants less than 6 months of age, and parent/guardian is unable or unwilling to suspend daycare for 28 days following inoculation

Any of the following events at the time of enrollment:

* fever (temporal or rectal temperature of greater than or equal to 100.4°F), or

* upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis) or

* nasal congestion significant enough to interfere with successful inoculation, or

* otitis media

Receipt of the following prior to enrollment:

* any killed vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or

* any live vaccine, other than rotavirus vaccine, within the 28 days prior, or

* another investigational vaccine or investigational drug within 28 days prior

Scheduled administration of the following after planned inoculation:

* killed vaccine or live-attenuated rotavirus vaccine within the 14 days after, or

* any live vaccine other than rotavirus in the 28 days after, or

* another investigational vaccine or investigational drug in the 56 days after

Receipt of immunoglobulin, any antibody products, or any blood products within the past 6 months

Receipt of any of the following medications within 3 days of study enrollment:

* systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or

* intranasal medications, or

* other prescription medication except as listed below

Receipt of salicylate (aspirin) or salicylate-containing products within the past 28 days

Born at less than 34 weeks gestation

Born at less than 37 weeks gestation and less than 1 year of age at the time of enrollment

Suspected or documented developmental disorder, delay, or other developmental problem

Previous receipt of supplemental oxygen therapy in a home setting

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

What this study is about

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

What this study is about